<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boltz, Kathy</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gadelha, Monica R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Biochemical Control of Acromegaly Continued in PAOLA Trial Extension</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-18 15:35:54</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">This extension study of the phase 3 PAOLA trial found that pasireotide LAR may be a viable, long-term treatment option for patients with acromegaly that is inadequately controlled with first-generation somatostatin analogues. Biochemical control of growth hormone and normalized insulin-like growth factor 1 continued through extension week 28.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>